Managing Pediatric Behavioral Health

Screens for and manages common pediatric behavioral and emotional conditions including anxiety, depression, disruptive behavior disorders, trauma/adverse childhood experiences (ACEs), and autism spectrum disorder. Applies validated screening tools, coordinates school-based services, and integrates collaborative care models for mental health in the pediatric primary care setting.

Why This Skill Exists

Mental health conditions affect 1 in 5 children, but fewer than half receive treatment. Pediatric primary care is the de facto mental health system for most children — wait times for child psychiatry average 6-8 months in many regions. The AAP and AACAP have promoted collaborative care models and universal mental health screening in primary care. This skill ensures every well-child and concern-driven visit includes validated screening, risk stratification, evidence-based initial management, and appropriate referral pathways.

Checkpoint A — Intake Verification

Required Intake Questions

What is the child's age (screening tools are age-specific)?
What is the primary behavioral/emotional concern (as described by parent, teacher, and/or child)?
When did symptoms begin and what was the temporal context (life event, school change, family stressor)?
How are symptoms affecting function (school performance, peer relationships, family dynamics, daily activities)?
Is there a family history of anxiety, depression, bipolar disorder, substance use, or suicide?
Has the child experienced trauma, abuse, neglect, or significant adverse childhood experiences?
Is the child currently receiving any behavioral health services (therapy, medication, school-based)?
What is the sleep pattern (insomnia, nightmares, excessive sleep)?
Are there any safety concerns (self-harm, suicidal ideation, aggression, homicidal ideation)?

Required Documents

Completed screening questionnaires (PHQ-A, GAD-7, SCARED, PSC, ACE questionnaire)
School records: report cards, behavioral reports, IEP/504 plan
Prior behavioral health evaluations or therapy notes
Medication history for psychotropic medications
Family psychosocial history

Step 1 — Universal Screening (Bright Futures Schedule)

Recommended Screening Tools by Age and Condition

| Age | Screening Tool | Target Condition | |-----|---------------|-----------------| | All ages | Pediatric Symptom Checklist (PSC-17 or PSC-35) | General psychosocial function | | 1-18 months | ASQ:SE-2 | Social-emotional development | | 4-17 | ACEs questionnaire (PEARLS or similar) | Adverse childhood experiences | | 8-17 | PHQ-2 → PHQ-A (if positive) | Depression | | 8-17 | SCARED (Screen for Child Anxiety Related Disorders) | Anxiety | | 12-18 | CRAFFT 2.1 | Substance use | | 18-24 months | M-CHAT-R/F | Autism spectrum disorder | | Any age with concern | Columbia Suicide Severity Rating Scale (C-SSRS) | Suicidal ideation/behavior |

Bright Futures Mental Health Screening Schedule

Depression screening: universally at age 12+ per USPSTF; earlier if clinical concern
Psychosocial screening: at every well-child visit (surveillance); formal screening per PSC at 4, 5, 6, 8, 10, 12, 14, 16, 18 years
Substance use: annually starting at age 12 (CRAFFT)
ACEs: at least once; ideally at initial visit and during high-risk periods

Step 2 — Anxiety Disorders

Common Presentations by Age

| Age | Common Anxiety Presentation | |-----|---------------------------| | Preschool | Separation anxiety, selective mutism | | School-age | Generalized anxiety, social anxiety, specific phobias | | Adolescent | Social anxiety, generalized anxiety, panic disorder |

SCARED Screening

41 items, parent and child versions; scores ≥ 25 (child) suggest significant anxiety
Subscales: panic/somatic, generalized anxiety, separation anxiety, social anxiety, school avoidance
Administer both parent and child versions for concordance analysis

Management

Mild-moderate: cognitive behavioral therapy (CBT) is first-line; evidence from CAMS study shows CBT alone effective in 60% of pediatric anxiety
Moderate-severe or CBT-insufficient: SSRI medication
- Fluoxetine: 5-10 mg → titrate to 20-40 mg (FDA-approved for OCD in children ≥ 7)
- Sertraline: 12.5-25 mg → titrate to 50-200 mg (FDA-approved for OCD in children ≥ 6)
- Escitalopram: 5 mg → titrate to 10-20 mg (FDA-approved for depression ≥ 12)
Combined CBT + SSRI: superior to either alone in moderate-severe anxiety (CAMS study)
Monitor for activation syndrome in first 2-4 weeks of SSRI (agitation, insomnia, worsening anxiety — not the same as suicidality)

FDA Black Box Warning

All antidepressants carry FDA black box warning for increased suicidal thinking/behavior in children and adolescents
Monitor closely: weekly for first 4 weeks, biweekly for next 4, monthly thereafter
Benefits of treatment generally outweigh risks for moderate-severe anxiety/depression

Step 3 — Depression

PHQ-A (Patient Health Questionnaire for Adolescents) Interpretation

| Score | Severity | Action | |-------|----------|--------| | 0-4 | Minimal | Continued surveillance | | 5-9 | Mild | Active monitoring; consider CBT | | 10-14 | Moderate | CBT and/or SSRI; behavioral health referral | | 15-19 | Moderately severe | SSRI + therapy; expedited referral | | 20-27 | Severe | Urgent referral; safety assessment |

Always Ask Question 9

PHQ-A item 9: "Thoughts that you would be better off dead or hurting yourself in some way"
ANY positive response requires immediate safety assessment using C-SSRS
Determine: passive ideation vs. active ideation; plan; means; intent; timeline
If active ideation with plan: do not leave child unsupervised; initiate crisis intervention

Treatment

Mild depression: active monitoring, psychoeducation, lifestyle interventions (exercise, sleep hygiene, social connection), supportive therapy
Moderate-severe: fluoxetine (only SSRI with FDA approval for depression in children ≥ 8) + CBT or interpersonal therapy (IPT-A)
Fluoxetine dosing: start 10 mg/day; may increase to 20 mg after 1-2 weeks if tolerated
If fluoxetine fails or is not tolerated: escitalopram, sertraline, or citalopram as alternatives
Avoid: paroxetine (negative studies in pediatrics), TCAs (cardiac risk), benzodiazepines for depression

Step 4 — Disruptive Behavior Disorders

Oppositional Defiant Disorder (ODD)

Pattern of angry/irritable mood, argumentative/defiant behavior, vindictiveness lasting ≥ 6 months
Differentiate from ADHD (impulsivity-driven defiance vs. deliberate opposition), anxiety (avoidance-driven refusal), and trauma (hyperarousal-driven aggression)
Management: parent management training (PMT) is the evidence-based treatment
- Programs: Triple P, Incredible Years, Parent-Child Interaction Therapy (PCIT)
- No FDA-approved medication for ODD; treat comorbid conditions (ADHD, anxiety)

Conduct Disorder (CD)

Persistent pattern of violating rights of others or age-appropriate societal norms
Four categories: aggression to people/animals, destruction of property, deceitfulness/theft, serious rule violations
Risk factors: family dysfunction, poverty, harsh parenting, peer deviance, callous-unemotional traits
Management: multisystemic therapy (MST), functional family therapy, therapeutic foster care; psychiatric referral for severe cases

Step 5 — Adverse Childhood Experiences (ACEs) and Trauma

ACEs Screening

Original ACE study (Felitti 1998): 10-item questionnaire covering abuse, neglect, household dysfunction
PEARLS (Pediatric ACEs and Related Life-events Screener): expanded validated tool for clinical use
ACE score ≥ 4: associated with dramatically increased risk of: depression, substance use, suicide attempts, chronic disease, early death
Screening identifies toxic stress exposure; does not diagnose PTSD

Trauma-Informed Response

Acknowledge the disclosure; express support without judgment
Assess current safety (is the child currently in a safe environment?)
Mandatory reporting if ongoing abuse or neglect is disclosed
Refer for trauma-focused CBT (TF-CBT) — the most evidence-based therapy for pediatric PTSD
Screening for trauma should NOT be a one-time event — revisit at subsequent visits

Building Resilience

Stable, nurturing caregiver relationship is the strongest protective factor
Encourage extracurricular activities, community connections, mentorship
Address caregiver stress and mental health (two-generation approach)

Step 6 — School-Based Coordination

School-Based Services

504 plan: for mental health conditions that substantially limit a major life activity (learning, concentrating, socializing)
IEP: if emotional disturbance qualifies under IDEA category "Emotional Disturbance" (ED)
School-based counseling, social skills groups, behavioral intervention plans

Communication with Schools

Obtain signed release of information from parent/guardian before communicating with school
Provide written recommendations for accommodations (specific, actionable)
Common accommodations: extended time, testing in separate room, reduced homework load, check-in with counselor, movement breaks, social skills groups

Crisis Planning

Safety plan for children with suicidal ideation or self-harm: should exist at home AND school
Safety plan components: warning signs, internal coping strategies, social contacts, adults who can help, professionals to contact, means restriction

Checkpoint B — Behavioral Health Review

[ ] Universal screening completed per Bright Futures schedule (PSC, PHQ-A, SCARED)
[ ] Positive screens followed up with validated assessment tools
[ ] Safety assessment completed (suicidal ideation, self-harm, homicidal ideation)
[ ] ACEs/trauma history obtained
[ ] Diagnosis established using DSM-5 criteria
[ ] Evidence-based treatment initiated (CBT, parent training, SSRI per indication)
[ ] FDA black box counseling documented (if SSRI prescribed)
[ ] SSRI monitoring schedule established (weekly × 4, biweekly × 4, then monthly)
[ ] School accommodations addressed (504/IEP referral, teacher communication)
[ ] Family psychoeducation provided
[ ] Follow-up plan specified with interval and escalation criteria
[ ] All [VERIFY] flags resolved or escalated

Quality Audit

| Item | Requirement | Pass? | |------|-------------|-------| | Screening completeness | Age-appropriate screening tool administered | | | Safety assessment | Suicidal ideation directly assessed; C-SSRS if positive | | | ACEs screening | Trauma history obtained | | | Diagnostic rigor | DSM-5 criteria explicitly applied | | | Treatment evidence | CBT/PMT/SSRI per guideline (not empiric benzodiazepines) | | | SSRI monitoring | Black box counseling + monitoring schedule documented | | | School coordination | Release signed; accommodations communicated | | | Family involvement | Psychoeducation provided; caregiver mental health assessed | | | Crisis plan | Safety plan created if suicidal ideation or self-harm | | | No unexplained [VERIFY] tags | All flagged items resolved or escalated | |

Guidelines

Follow AAP 2018 Mental Health Competencies for Pediatric Practice
Apply USPSTF recommendation for depression screening in adolescents (grade B, ages 12-18)
Use PHQ-A (modified PHQ-9 for adolescents) as primary depression screen
Use SCARED as primary anxiety screen (validated for ages 8-18)
Follow AACAP Practice Parameters for: anxiety (2007), depression (2007), ODD/CD (2007), PTSD (2010)
CAMS study: combined CBT + sertraline superior to either alone for moderate-severe pediatric anxiety
TADS study: combined fluoxetine + CBT superior for adolescent depression; fluoxetine alone superior to CBT alone for depression
Fluoxetine is the only SSRI with FDA approval for pediatric depression (ages ≥ 8)
FDA black box: monitor all antidepressants closely for suicidal thinking in children/adolescents
Collaborative care models (e.g., MCPAP, Project ECHO): leverage psychiatric consultation for primary care-based management
Never prescribe benzodiazepines for pediatric anxiety or depression as first-line treatment
This skill produces clinical documentation; it does not replace clinical judgment